Concepedia

Huamao Mark Lin

HM

37

Publications

2.1K

Citations

22

H-Index

1998

Active since

Affiliations

Takeda (United States)(Current)

Millennium Engineering and Integration (United States)

Dana-Farber Cancer Institute

Seoul National University Hospital

Royal Marsden Hospital

Huamao Mark Lin is an author at Takeda (United States) specializing in medicine, oncology, and immunology.

ORCID

Top concepts

Publications per year

1998–2025

37

Publications

37

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Clinical Oncology · 2020 · 361 citations · Full text

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · Journal of Thoracic Oncology · 2021 · 350 citations · Full text

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim et al. · JAMA Oncology · 2021 · 282 citations · Full text

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer

Gerald S. Falchook, Robert L. Coleman, A. Roszak et al. · JAMA Oncology · 2018 · 88 citations · Full text

The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester et al. · European Urology · 2020 · 71 citations · Full text

Rows per page

1–5 of 37